mounjaro or tirzepatide Safety and Effectiveness of Tirzepatide
Description
GLP1-s work best as long-term medications
Semaglutide 2.4 mg, an anti-obesity medication (AOM) recently approved by the US Food and Drug Administration, has demonstrated clinically relevant weight loss in its phase 3 clinical trials
The STEP clinical trials documented average weight loss of 15% body weight at therapeutic doses over 68 weeks
240 mL) or reference (fasting overnight until 30 min post-dose
See the real numbers, key differences, and which one fits your goals.
